Background: To investigate the dermal uptake of 4,4′-diphenylmethane diisocyanate (4,4′-MDI) a study was performed where two female volunteers were exposed to 10 and 25 mg respectively of 4,4-MDI by applying 2.0% 4,4′-MDI in petrolatum over areas where the surface concentration corresponded to 800 µg/cm 2 . 10 days later they developed eczematous dermatitis at the area of application.
Introduction
Isocyanates are established as a cause of occupational asthma and there are specific threshold limit values for airborne exposure to them. However, there are suggestions that dermal exposure may be of importance for the induction of respiratory diseases (1) . Little is known about the dermal uptake of isocyanates and to study this topic further, a study was initiated in order to investigate the cutaneous uptake of a commonly used industrial isocyanate, 4,4′-diphenylmethane diisocyanate (4,4′-MDI) (2) . In a pre-study, two volunteers were recruited to determine the exposure necessary to enable detection of markers of exposure in blood and urine. After this pre-study both volunteers developed an eczematous dermatitis corresponding to the exact areas of application. This indicated 4,4′-MDI sensitization and the study was interrupted. The aim of the present investigation was to determine if the application had caused active sensitization to 4,4′-MDI in the two volunteers.
Materials and Methods

Volunteers
Both volunteers gave written informed consent to participate in the study, which was approved by the Research Ethics Committee of Umeå University (Dnr 09-214M), Sweden.
They were healthy females at the age of 19 and 35 years, with no previous history of contact allergy to isocyanates or any respiratory symptoms that could be related to isocyanates. The original exposures and the investigation of the suspected sensitization were carried out at the Department of Occupational and Environmental Dermatology, Malmö.
Chemicals and materials
The chemicals that were used in this study were the following: 4,4′-MDI and 4,4′-diaminodiphenylmethane (4,4′-MDA) (TCI Europe, Zwijnderecht, Belgium), p- 
Dermal Uptake Study
The 4,4′-MDI preparation 2.0 % w/w in petrolatum, for the dermal uptake study was made at To each impinger sample an aliquot of 50 µl 2.0 µg/ml 4,4′-MDI-D 9 DBA was added as internal standard. The samples were ultrasonicated at 20°C for 5 minutes and then each sample was divided into 10 ml subsamples. The subsamples were evaporated until approximately 1.5 ml remained, then the subsamples were pooled and evaporated to dryness using a vacuum centrifuge (AES2010, Savant Instruments Inc, Holbrook, NY, USA). A set of 10.0 ml toluene (zero samples) and calibration solutions all with internal standard were evaporated with the impinger samples. The dry samples were reconstituted with 0.50 ml acetonitrile, ultrasonicated for 1 minute and filtered using a Titan ® 17 mm 0.22 µm nylon syringe filter (SunSRi, Duluth, USA). An aliquot of the impinger samples were diluted with a zero sample to calibrated range (0.010-0.56 µg/ml). The samples were analysed using liquid chromatography-mass spectrometry on an Agilent 1100 Series HPLC/MS instrument, consisting of: a vacuum degasser G1322A, a binary pump G1312A, an autosampler G1329 A with a thermostat G1330A (Hewlett Packard, Waldbronn, Germany), a mass-selective detector G1946B with an electrospray interface G1948A (Hewlett Packard, Palo Alto, USA).
Sampling and chemical analysis
Data generated by the HPLC/MS were collected and evaluated using the software LC/MSD Chemstation A.10.02 (Agilent technologies, Waldbronn, Germany). 10 µl of each sample were injected using segmented injection with deionised water (25 µl water-10 µl sample-25.
µl water). Chromatographic separation was performed on a Hypersil Gold™ column (100 × 2.1 mm, 3.0 µm, Thermo Electron Corporation, Waltham, USA) using gradient elution, see 
Results
Of the total amount of 4,4′-MDI applied during the dermal uptake study, i.e. 10.0 mg and 25.0 mg , 7.0 (70%) and 17.5 mg (70%) was recovered, respectively ( Table 2 ). 7 to 10 days after this study an itchy eczema appeared corresponding to the area of application on both volunteers. The mean concentration of 4,4′-MDI found in the analysed petrolatum preparations was 1.9% w/w (Table 3) . Results from patch testing of 4,4′-MDI, 4,4′-MDA, PPD and DMDI are given in Table 4 . Active sensitization is traditionally defined as a negative patch test reaction followed by a flare-up reaction after D10 to D20, and with a positive reaction on D2 to D4 at retest (6) . A positive reaction on the second patch test occasion could also represent an increase in the level of sensitivity, but if patch testing on this test occasion is done with the substance diluted 10-100× as compared with the original test concentration, and the test turns out positive, active sensitization is the most likely (6). Since the volunteers had showed such strong flareup reactions at the site of the provocation they were not tested with the highest concentration of 4,4′-MDI, i.e. 2.0%, and thus no retest was performed with the same concentration as the one used at the suspected active sensitization. Only one of the volunteers reacted to the diluted preparations of 4,4′-MDI and that was on D7. In our experience at the Malmö department, patch testing with 4,4′-MDI can be difficult since there can be significant individual variation in test response from one test occasion to another and we have seen a case where the same patient exhibited both early, late, and no reaction at all to 4,4′-MDI when tested on different occasions (5) . Based solely upon the testing with diluted preparations of 4,4′-MDI, the results do not fulfil the criterions described above for establishing that active sensitization had occurred in both volunteers, since one did not react to 4,4′-MDI. Still, we consider it most certain that both volunteers had been sensitized through the dermal uptake since they both reacted to 4,4′-MDA, which is a marker of 4,4′-MDI allergy (5).
Discussion
The concentration of the 4,4′-MDI preparation used for the dermal uptake study was confirmed to be 1.9% w/v, which is very close to the intended concentration of 2.0%. We also confirmed that the dose/area unit was close to the intended 800 µg/cm 2 , the calculated dose used earlier for 4,4′-MDI patch testing. It is considered that the vital factor for sensitization is the dose/area unit rather than the exposed area (7) and this is the background for choosing the concentration and the dose/area unit for the dermal uptake study. At this concentration 2 volunteers were sensitized and the only possible explanation is that 2.0% MDI concentration is high enough to cause active sensitization.
We September 2010 (9) . It is also interesting that active sensitization occurred although only around 30% of the 4,4′-MDI in the uptake study could have been absorbed by the skin ( Table   2 ) which indicates that 4,4′-MDI is a strong sensitizer.
that PPD could have been the primary sensitizer, which could cause cross-reactions to 4,4′-MDI and 4,4′-MDA (Table 4) . However, no reactions to PPD were seen. DMDI has been reported to cross-react to 4,4′-MDI (10) but this could not be shown in the present study (Table 4 ). The deviation from the intended equimolar concentrations of PPD and DMDI is considered too small to affect the patch test results.
Conclusion
Dermal application with preparations of 2.0% 4,4′-MDI, corresponding to a surface concentration of 800 µg/cm 2 , caused active sensitization in two volunteers. Thus, there is a risk that patch testing with the same concentration can cause active sensitization. Based on these results the ESCD recommends that the patch test concentration of 4,4′-MDI should be lowered to 0.50% w/w. 
